Solet's take a closerlookbecauseinterimresultsforthisphasethreetrialsshowthatthevaccineis 94.5% effectiveatstoppingsymptomaticinfections, itcanbetransported a standardfreezertemperatureofaroundminus 20 degreesCelsius, whichcouldbe a significantbenefitoverfightersvaccine, whichneedstobestoredatminus 70.
It's been a longyearformanyofusonthatourcompanyhasbeen a long, hardslogtogettothepointwherewenowhaveclearevidenceofefficacy, thevaccinetopreventcovert 19 diseaseTherewas a momentofprettyintenserelief.
But, um, clearly a n'importemilestonein a greatmilestoneforusas a companyandhopefullyforus, moregenerallyaswefightthispandemic, whereit's talknowtoDrMariaSundaramhasaninfectiousdiseaseexpertfortheInstituteforClinicalEvaluationSciencesinTorontoandjoinsmelivehereontheprogram.
Sothenumberofcasesthatwe'reseeinginthemodern a trialthatarebeingreportedintheseinterimresultsarepromisingthatthis 94.5% effectivenessestimateisreallyverymuchtruerepresentationofwhatwecanexpecttoseein a broadergroupofpeople.